# SEC Form 4

П

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5
obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

#### OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person <sup>*</sup> FARRELL STEPHEN C			2. Issuer Name <b>and</b> Ticker or Trading Symbol BIOTIME INC [ BTX ]		tionship of Reporting Pe all applicable) Director	erson(s) to Issuer 10% Owner
(Last) 3021 NE 23	(First) 3 COURT	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 07/01/2017		Officer (give title below)	Other (specify below)
(Street) FORT LAUDERDA	DALE FL	33305	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Fili Form filed by One Re Form filed by More th Person	porting Person
(City)	(State)	(Zip)				

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
		Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)		
							97,450	D			
	2. Transaction Date	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transa Code ( 8)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8)	2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8)4. Securities / Disposed Of 5)	2. Transaction Date (Month/Day/Year) 2. Transaction (Month/Day/Year) 2. Transaction if any (Month/Day/Year) 2. Transaction Code (Instr. 8) 2. Transaction Code (Instr. 8)	2. Transaction Date (Month/Day/Year) 2. Transaction (Month/Day/Year) 2. Transaction Code (Instr. 8) 2. Transaction Code (Instr. 8)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction (B) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 6. Ownership Form: Direct (D) or Indirect (1) (Instr. 4)		

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ve es d ed nstr.	6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to Purchase Common Shares	\$3.15	07/01/2017		A		20,000		(1)	06/30/2022	Common Shares	20,000	\$0.00	20,000	D	
Option to Purchase Common Shares	\$2.72							(2)	06/30/2021	Common Shares	20,000		20,000	D	
Option to Purchase Common Shares	\$3.57							(3)	06/30/2020	Common Shares	20,000		20,000	D	
Option to Purchase Common Shares	\$3.11							(4)	06/30/2019	Common Shares	20,000		20,000	D	
Option to Purchase Common Shares	\$4.13							(5)	06/30/2018	Common Shares	20,000		20,000	D	
Option to Purchase Common Shares	\$4.12							(6)	03/10/2018	Common Shares	20,000		20,000	D	

Explanation of Responses:

1. Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors.

2. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.

3. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.

4. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.

5. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013.

6. Became exercisable in four equal quarterly installments after the date of grant on March 11, 2013.

Remarks:

## /s/Stephen C. Farrell

\*\* Signature of Reporting Person

07/05/2017

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.